Progenics Pharmaceuticals and Wyeth announced that the FDA has approved Relistor (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Wyeth said it expects to make Relistor available in the US in early June.
Lupin Pharmaceuticals has announced its launch of Suprax 400 mg tablets (cefixime USP) in the US. This line extension further extends the brand franchise of Lupin's flagship anti-infective oral suspension brand. With Suprax 400 mg tablets, Lupin aims to to further increase its share of the $450 million antibiotic market for the treatment of urinary tract infections and extend use of Suprax to the patient population of children of ages 12 and older.